Riverhead Capital Management LLC reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,476 shares of the medical equipment provider’s stock after selling 27 shares during the quarter. Riverhead Capital Management LLC’s holdings in Zimmer Biomet Holdings were worth $1,217,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of ZBH. BlackRock Inc. lifted its position in shares of Zimmer Biomet Holdings by 4,042.4% in the first quarter. BlackRock Inc. now owns 16,740,383 shares of the medical equipment provider’s stock valued at $2,044,168,000 after acquiring an additional 16,336,262 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Zimmer Biomet Holdings by 92.7% in the second quarter. JPMorgan Chase & Co. now owns 3,279,951 shares of the medical equipment provider’s stock valued at $421,146,000 after acquiring an additional 1,577,874 shares in the last quarter. Harbour Capital Advisors LLC lifted its position in shares of Zimmer Biomet Holdings by 13,131.3% in the second quarter. Harbour Capital Advisors LLC now owns 1,302,618 shares of the medical equipment provider’s stock valued at $10,145,000 after acquiring an additional 1,292,773 shares in the last quarter. Nordea Investment Management AB lifted its position in shares of Zimmer Biomet Holdings by 25.0% in the first quarter. Nordea Investment Management AB now owns 4,931,281 shares of the medical equipment provider’s stock valued at $602,159,000 after acquiring an additional 987,398 shares in the last quarter. Finally, Glenview Capital Management LLC purchased a new stake in shares of Zimmer Biomet Holdings in the first quarter valued at $94,197,000. Institutional investors and hedge funds own 85.48% of the company’s stock.

In other news, VP Tony W. Collins sold 16,986 shares of Zimmer Biomet Holdings stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $121.74, for a total value of $2,067,875.64. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.07% of the company’s stock.

Zimmer Biomet Holdings, Inc. (NYSE ZBH) opened at 115.47 on Friday. The stock has a market cap of $23.35 billion, a P/E ratio of 32.89 and a beta of 1.21. Zimmer Biomet Holdings, Inc. has a one year low of $95.63 and a one year high of $133.49. The company has a 50-day moving average price of $114.88 and a 200-day moving average price of $120.74.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.10 by ($0.02). The company had revenue of $1.95 billion for the quarter, compared to the consensus estimate of $1.95 billion. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. Zimmer Biomet Holdings’s quarterly revenue was up 1.1% on a year-over-year basis. During the same quarter last year, the business earned $2.02 earnings per share. On average, analysts anticipate that Zimmer Biomet Holdings, Inc. will post $8.24 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 22nd will be paid a $0.24 dividend. The ex-dividend date is Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.83%. Zimmer Biomet Holdings’s payout ratio is presently 27.59%.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.dailypolitical.com/2017/09/17/riverhead-capital-management-llc-sells-27-shares-of-zimmer-biomet-holdings-inc-zbh.html.

Several analysts have recently issued reports on the company. Stifel Nicolaus restated a “hold” rating and issued a $125.00 price objective on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Gabelli assumed coverage on Zimmer Biomet Holdings in a research report on Thursday, August 24th. They issued a “buy” rating and a $142.00 price objective on the stock. Zacks Investment Research downgraded Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 8th. BMO Capital Markets restated a “buy” rating and issued a $136.00 price objective on shares of Zimmer Biomet Holdings in a research report on Tuesday, July 11th. Finally, Wells Fargo & Company restated a “market weight” rating on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Four analysts have rated the stock with a sell rating, seven have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $136.75.

Zimmer Biomet Holdings Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.